A Phase 3 interventional study of Naproxen Sodium ER (BAYH6689) in Pain, sponsored by Bayer. Completed at 24 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-08-25.
Sponsored by Bayer · Phase 3 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.
Among the 25 studies testing naproxen in Pain, this one is the 3rd largest by enrollment, is one of 3 that started in 2008, is one of 5 in phase 3, and was the 3rd registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:
American University of Beirut Medical Center · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 497 is above the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 100 across the 25 interventional studies. Of the 22 that completed or were terminated, 13 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 25 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
14 studies in Pain by Bayer: none open now, none under way, none of them phase 3. Of 14 finished, 5 (36%) have results posted.
Among the 14 studies in Pain by Bayer, this one is the 2nd largest by enrollment, is one of 2 that started in 2008, is one of 4 in phase 3, and was the 1st registered.
Bayer’s Pain studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing naproxen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 14 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this Study is to assess how subjects will use the investigational product in an uncontrolled, naturalistic environment.
Issues on adverse event data are addressed in the Adverse Event section.
The following acronyms and abbreviations were used in the results section.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subjects take one tablet Naproxen Sodium ER (extended release) every 24 hours while symptoms last for no more than 10 consecutive days for pain and no more than 3 consecutive days for fever
Drug: Naproxen Sodium ER (BAYH6689)
Consumer use of Extended Release Naproxen Sodium
Use Days With One or More Misuse Occasions
Misuse occasion: any reported use of 2 or more tablets within a 22 hour period (included use of 2 tablets in 1 dose or the use of 1 tablet at one time and 1+ tablets at a later time within the same 22 hour period). Use-days were calculated based on days in which there was subject-reported product consumption, meaning that if a tablet was consumed on a day this resulted in 1 use-day. If a subject reported product consumption on 3 different days this resulted in 3 use-days. The cumulative expression of use-days is the total number of use-days reported by all subjects with follow up data.
Time frame: 1 month
Dosing Occasions With One and More Than One Tablet Taken
Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.
Time frame: 1 month
Use Days With and Without Next Dose Less Than 22 Hours Later
Use-days were calculated based on days in which there was subject-reported product consumption, meaning that if a tablet was consumed on a day this resulted in one use-day. If a subject reported product consumption on three different days this resulted in three use-days. The cumulative expression of use-days is the total number of use-days reported by all subjects with follow up data.
Time frame: 1 month
Number of Subjects With and Without More Than One Tablet Taken Per Dose
Time frame: 1 month
Number of Subjects With and Without Next Dose Less Than 22 Hours Later
This Outcome is a measure of subjects while Outcome Measure 3 provides the outcome as a measure of cumulative number of use-days for all subjects involved.
Time frame: 1 month
Number of Subjects With and Without More Than 660 mg at Least Once
This measure refers to number of subjects that exceeded 660 mg of naproxen sodium per day at least once during the reporting period. The maximum dose (660 mg) may have been exceeded with one dose (if a subject consumed two tablets in one dosing occasion) or may have been exceeded throughout the course of a use-day (if a subject took one tablet in one dosing occasion and then later in the same day took one or more tablets in another dosing occasion).
Time frame: 1 month
Average Daily Dose
Time frame: 1 month
Number of Subjects That Have Taken Study Drug on More Than 10 Consecutive Days and Not on More Than 10 Consecutive Days
This measure is reporting how many subjects exceeded the label limit for consecutive days of study drug dosing
Time frame: 1 month
Number of Total Dosing Occasions Per Subject
Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.
Time frame: 1 month
Number of Dosing Occasions Per Subject That Exceeded 660 mg
Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.
Time frame: 1 month
Recruitment for the study was conducted using newspaper ads, direct mailing, in-store pharmacy posters, and flyers. Potential subjects who learned about the study through local advertising were directed to call a toll-free number (call center at the CRO (Contract Research Organization)) where minimal screening questions were asked.
| Milestone | Naproxen Sodium ER (BAYH6689) |
|---|---|
| Started | 497 |
| Subjects provided drug | 497 |
| Subjects consumed drug | 485 |
| Subjects provided detailed use data | 467 |
| Completed | 487 |
| Not completed | 10 |
| Withdrew: Lost to follow-up | 10 |
Misuse occasion: any reported use of 2 or more tablets within a 22 hour period (included use of 2 tablets in 1 dose or the use of 1 tablet at one time and 1+ tablets at a later time within the same 22 hour period). Use-days were calculated based on days in which there was subject-reported product consumption, meaning that if a tablet was consumed on a day this resulted in 1 use-day. If a subject reported product consumption on 3 different days this resulted in 3 use-days. The cumulative expression of use-days is the total number of use-days reported by all subjects with follow up data.
| days | Naproxen Sodium ER (BAYH6689) |
|---|---|
| use days without a misuse occasion | 2112 |
| use days with a misuse occasion | 294 |
Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.
| dosing occasions | Naproxen Sodium ER (BAYH6689) |
|---|---|
| only one tablet taken | 2500 |
| more than one tablet taken | 66 |
Use-days were calculated based on days in which there was subject-reported product consumption, meaning that if a tablet was consumed on a day this resulted in one use-day. If a subject reported product consumption on three different days this resulted in three use-days. The cumulative expression of use-days is the total number of use-days reported by all subjects with follow up data.
| days | Naproxen Sodium ER (BAYH6689) |
|---|---|
| no dose less than 22 hours later | 2175 |
| at least one dose less than 22 hours later | 231 |
| participants | Naproxen Sodium ER (BAYH6689) |
|---|---|
| never took more than one tablet per dose | 440 |
| took more than one tablet per dose | 27 |
This Outcome is a measure of subjects while Outcome Measure 3 provides the outcome as a measure of cumulative number of use-days for all subjects involved.
| participants | Naproxen Sodium ER (BAYH6689) |
|---|---|
| no doses less than 22 hours later | 359 |
| at least one dose less than 22 hours later | 108 |
This measure refers to number of subjects that exceeded 660 mg of naproxen sodium per day at least once during the reporting period. The maximum dose (660 mg) may have been exceeded with one dose (if a subject consumed two tablets in one dosing occasion) or may have been exceeded throughout the course of a use-day (if a subject took one tablet in one dosing occasion and then later in the same day took one or more tablets in another dosing occasion).
| participants | Naproxen Sodium ER (BAYH6689) |
|---|---|
| not more than 660 mg | 344 |
| more than 660 mg at least once | 123 |
| mg | Naproxen Sodium ER (BAYH6689) |
|---|---|
| Average Daily Dose | 722 ± 233.4 |
This measure is reporting how many subjects exceeded the label limit for consecutive days of study drug dosing
| participants | Naproxen Sodium ER (BAYH6689) |
|---|---|
| not more than 10 consecutive days | 376 |
| more than 10 consecutive days | 109 |
Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.
| dosing occasions | Naproxen Sodium ER (BAYH6689) |
|---|---|
| Number of Total Dosing Occasions Per Subject | 5.5 ± 3.7 |
Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.
| dosing occasions | Naproxen Sodium ER (BAYH6689) |
|---|---|
| Number of Dosing Occasions Per Subject That Exceeded 660 mg | 0.6 ± 1.6 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naproxen Sodium ER (BAYH6689) | — | 3/485 (0.6%) | 111/485 (22.9%) |
| Event | Naproxen Sodium ER (BAYH6689) |
|---|---|
| CellulitisInfections and infestations | 1/485 |
| SepsisInfections and infestations | 1/485 |
| Renal impairmentRenal and urinary disorders | 1/485 |
| Event | Naproxen Sodium ER (BAYH6689) |
|---|---|
| DyspepsiaGastrointestinal disorders | 10/485 |
| HeadacheNervous system disorders | 10/485 |
| NauseaGastrointestinal disorders | 8/485 |
| Abdominal pain upperGastrointestinal disorders | 7/485 |
| DiarrhoeaGastrointestinal disorders | 7/485 |
| ConstipationGastrointestinal disorders | 6/485 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/485 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/485 |
| FlatulenceGastrointestinal disorders | 4/485 |
| NasopharyngitisInfections and infestations | 4/485 |
| Age, Continuous(years) | Naproxen Sodium ER (BAYH6689) |
|---|---|
| Mean | 49.8 ± 15.1 |
| Sex: Female, Male(Participants) | Naproxen Sodium ER (BAYH6689) |
|---|---|
| Female | 292 |
| Male | 205 |
| Education(participants) | Naproxen Sodium ER (BAYH6689) |
|---|---|
| 8th grade or less | 6 |
| Some high school | 21 |
| High school graduate, GED, or certificate | 119 |
| Some college or technical school | 185 |
| College graduate | 117 |
| Post-graduate degree | 49 |
| Missing | 0 |
| Literacy(participants) | Naproxen Sodium ER (BAYH6689) |
|---|---|
| Normal | 437 |
| Low | 56 |
| No REALM Score | 4 |
| Prior Analgesic Use(participants) | Naproxen Sodium ER (BAYH6689) |
|---|---|
| Heavy | 148 |
| Regular | 349 |
| Race(participants) | Naproxen Sodium ER (BAYH6689) |
|---|---|
| White | 399 |
| Black | 56 |
| Hispanic | 3 |
| Asian | 8 |
| Other | 31 |
| Missing | 0 |
The record gives a start of Jul 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 2 years 6 months after primary completion. A results delay was requested in Dec 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen